Tyrosine kinase inhibitorFDA-approvedSecond-line
Ponatinib
How it works
Blocks multiple tyrosine kinases involved in cancer growth, including BCR-ABL, T315I, and others.
Cancer types
Leukemia— BCR-ABL-positive
Efficacy
In clinical trials, around 30% of BCR-ABL-positive patients achieved a major cytogenetic response, with a median progression-free survival of approximately 1 year.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Combination Therapy for CD22-Positive B-Lineage Acute Lymphoblastic Leukemia | Leukemia | phase-2 | — | Source → |
| Evaluating Ponatinib Hydrochloride for Chronic Myeloid Leukemia | Leukemia | phase-2 | — | Source → |
| Combining Ponatinib and Vitamin K2 May Help Treat Acute Myeloid Leukemia | Leukemia | lab-study | — | Source → |
| Choosing the Right Second-Line Treatment for Chronic Myeloid Leukemia | Leukemia | review | — | Source → |
| Ponatinib Improves Quality of Life for Leukemia Patients | Leukemia | phase-3 | — | Source → |
| Ponatinib-based therapy shows promise for CML in myeloid blast phase | Leukemia | phase-2 | The rate of morphological remission with or without count recovery (i.e. overall response rate [ORR]) was 49%. | Source → |
| Combining Two Leukemia Treatments Shows Promise in Lab Experiments | Leukemia | lab-study | — | Source → |
| Ponatinib vs Imatinib for Leukemia Treatment: Cost Comparison | Leukemia | phase-3 | Ponatinib offered an approximate gain of 3 months of life and 6 months of quality-adjusted life. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.